Men's Sexual Health

A special issue of Medical Sciences (ISSN 2076-3271).

Deadline for manuscript submissions: closed (30 November 2019) | Viewed by 53476

Special Issue Editor

Prof. Dr. Eric Chung
E-Mail Website
Guest Editor
Andro Urology, University of Queensland, Brisbane 4000, Australia
Interests: erectile dysfunction; Peyronie's disease; urinary incontinence; prosthesis reconstruction

Special Issue Information

Dear Colleagues,

Significant advances have been made in the field of men’s sexual health (MSH) in recent years. The introduction of new and novel technologies to diagnose and manage various sexual health conditions has revolutionised the ways in which we approach and provide evidence-based medicine healthcare for effective outcomes.

This Special Issue will address controversial areas as well as provide critical reviews of important topics in MSH. This Special Issue will feature short, focused reviews, including an update on the advances and challenges in the latest trends in MSH. The goals of publication are to deliver state-of-art information on emerging ideas as well as to reassess contemporary management strategies on key aspects of MSH.

I hope that this Special Issue will serve as an informative and enjoyable reference to readers on a diverse group of sexual medicine related topics.

We look forward to receiving your contributions.

Prof. Dr. Eric Chung
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medical Sciences is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Current limitations in medical therapy for Peyronie’s disease: Should medical therapy be offered?
  • Penile prosthesis implant: Addressing the current limitations of conventional medical therapy in erectile dysfunction
  • Sexual health, cardiovascular risk modification, and exercise program: Concept in prostate cancer survivorship
  • Sexuality, sexual health, and ageing population
  • Imaging modalities in prostate cancer: Revolutionizing the way we image prostate cancer
  • Low-intensity shockwave therapy for men with erection dysfunction: From concept to clinical applications
  • Genetic markers for prostate cancer diagnosis and prognosis: Improving the detection and management
  • Novel and standard imaging studies for Peyronie’s disease: Imaging the penis
  • Prostate cancer survivorship on erectile and sexual dysfunction: Evaluating the “real data” and current strategies to penile rehabilitation

Published Papers (9 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 276 KiB  
Review
The Interplay between Vascular Function and Sexual Health in Prostate Cancer: The Potential Benefits of Exercise Training
Med. Sci. 2020, 8(1), 11; https://doi.org/10.3390/medsci8010011 - 11 Feb 2020
Cited by 5 | Viewed by 3172
Abstract
Prostate cancer and its associated treatments can cause significant and lasting morbidities, such as cardiovascular and sexual dysfunctions. Various interventions have attempted to prevent or mitigate these dysfunctions. This review summarises the available evidence on the effects of exercise training on markers of [...] Read more.
Prostate cancer and its associated treatments can cause significant and lasting morbidities, such as cardiovascular and sexual dysfunctions. Various interventions have attempted to prevent or mitigate these dysfunctions. This review summarises the available evidence on the effects of exercise training on markers of cardiovascular disease (as assessed via vascular health outcomes) and sexual health in this prevalent cancer population. Current studies predominantly report blood pressure outcomes as a marker of vascular health, as well as various questionnaires assessing sexual health parameters, in men on active treatment (i.e., hormone or radiation therapies) or post-treatment. Preliminary evidence suggests that exercise interventions may elicit improvements in sexual function, but not blood pressure, in these populations. Future studies in more advanced and varied prostate cancer populations (i.e., those on chemotherapies or immunotherapies, or undergoing active surveillance) are required to ascertain the duration, intensity and frequency of exercise that optimises the effects of exercise training on cardiovascular and sexual dysfunctions (and their relationship) in men during and following treatment for prostate cancer. Full article
(This article belongs to the Special Issue Men's Sexual Health)
12 pages, 238 KiB  
Review
Ejaculatory and Orgasmic Dysfunction Following Prostate Cancer Therapy: Clinical Management
Med. Sci. 2019, 7(12), 109; https://doi.org/10.3390/medsci7120109 - 10 Dec 2019
Cited by 5 | Viewed by 3963
Abstract
The majority of sexual health research has focused on erectile dysfunction following prostate cancer treatment. Ejaculatory and orgasmic dysfunction are significant side effects following the treatment of prostate cancer. Orgasmic dysfunction covers a range of issues including premature ejaculation, anorgasmia, dysorgasmia, and climacturia. [...] Read more.
The majority of sexual health research has focused on erectile dysfunction following prostate cancer treatment. Ejaculatory and orgasmic dysfunction are significant side effects following the treatment of prostate cancer. Orgasmic dysfunction covers a range of issues including premature ejaculation, anorgasmia, dysorgasmia, and climacturia. This review provides an overview of prevalence and management options to deal with orgasmic dysfunction. A Medline Pubmed search was used to identify articles relating to these problems. We found that orgasmic dysfunction has a very large impact on patients’ lives following prostate cancer treatment and there are ways for physicians to treat it. Management of patients’ sexual health should be focused not only on erectile dysfunction, but on orgasmic dysfunction as well in order to ensure a healthy sexual life for patients and their partners. Full article
(This article belongs to the Special Issue Men's Sexual Health)
11 pages, 843 KiB  
Review
Premature Ejaculation: Aetiology and Treatment Strategies
Med. Sci. 2019, 7(11), 102; https://doi.org/10.3390/medsci7110102 - 25 Oct 2019
Cited by 40 | Viewed by 14169
Abstract
Premature ejaculation (PE) is a highly prevalent male sexual dysfunction that is often neglected, presenting a currently unmet therapeutic need. The classification of PE has historically been varied and at times ambiguous, contributing to inaccurate prevalence estimates. This review uses the International Society [...] Read more.
Premature ejaculation (PE) is a highly prevalent male sexual dysfunction that is often neglected, presenting a currently unmet therapeutic need. The classification of PE has historically been varied and at times ambiguous, contributing to inaccurate prevalence estimates. This review uses the International Society for Sexual Medicine (ISSM) definition of PE, which includes reduced ejaculatory latency, lack of control and associated negative personal consequences. Patient assessment and management options differ depending on the classification of PE and it is the role of the clinician to appropriately classify patients and be aware of the correct management strategies. This review provides an overall background of PE in terms of classification and underlying physiology, patient assessment and management strategies along with the scientific rationale for treatment. Patients with lifelong and acquired PE are most likely to benefit from combination therapy of pharmacological treatment in the form of selective serotonin re-uptake inhibitor dapoxetine, psychosexual behavioural therapy and psychological therapy. Full article
(This article belongs to the Special Issue Men's Sexual Health)
Show Figures

Figure 1

7 pages, 196 KiB  
Review
Sexuality in Ageing Male: Review of Pathophysiology and Treatment Strategies for Various Male Sexual Dysfunctions
Med. Sci. 2019, 7(10), 98; https://doi.org/10.3390/medsci7100098 - 20 Sep 2019
Cited by 10 | Viewed by 4917
Abstract
Sexual function among older men is often thought to decrease as part of normal ageing biology despite the fact that sexuality remains an important issue in the elderly. Sexual dysfunction in the aged male is likely multifactorial in nature, with the development and/or [...] Read more.
Sexual function among older men is often thought to decrease as part of normal ageing biology despite the fact that sexuality remains an important issue in the elderly. Sexual dysfunction in the aged male is likely multifactorial in nature, with the development and/or progression of medical comorbidities often resulting in decline in male sexual function and poor treatment response. At present, sexual dysfunction in the ageing male is poorly investigated and understood, and current treatment strategies aim at improving sexual desire and erectile function with limited data on ejaculatory and orgasmic dysfunctions. In addition, men are often reticent to seek help for health concerns including sexual dysfunction. The following article provides a narrative review of strategies to address various aspects of sexual dysfunction in the ageing male. Clinicians need to be educated to be sensitive when discussing sexuality issues among older men and to present practical solutions that take into account individual and cultural differences. Full article
(This article belongs to the Special Issue Men's Sexual Health)
16 pages, 287 KiB  
Review
Medical Management of Peyronie’s Disease: Review of the Clinical Evidence
Med. Sci. 2019, 7(9), 96; https://doi.org/10.3390/medsci7090096 - 18 Sep 2019
Cited by 5 | Viewed by 5392
Abstract
Peyronie’s disease is a condition that causes abnormal healing of the tunica albuginea, causing penile curvature. It is difficult to treat and its management is continuing to evolve. Proposed non-surgical treatments have included oral, topical, intralesional, extracorporeal shockwave, and traction therapy. The study [...] Read more.
Peyronie’s disease is a condition that causes abnormal healing of the tunica albuginea, causing penile curvature. It is difficult to treat and its management is continuing to evolve. Proposed non-surgical treatments have included oral, topical, intralesional, extracorporeal shockwave, and traction therapy. The study of Peyronie’s disease is made difficult by heterogeneity in the timing of presentation, severity and characteristics of deformity, and associated complaints. Moreover, meta-analyses of studies are difficult due to inconsistencies across study endpoints and the duration of treatments. This article reviews the current clinical evidence and guideline recommendations, with a focus on an improvement in penile curvature. Full article
(This article belongs to the Special Issue Men's Sexual Health)
11 pages, 268 KiB  
Review
A Review of Current and Emerging Therapeutic Options for Erectile Dysfunction
Med. Sci. 2019, 7(9), 91; https://doi.org/10.3390/medsci7090091 - 29 Aug 2019
Cited by 15 | Viewed by 9304
Abstract
Contemporary treatment algorithms for erectile dysfunction (ED) involve the use of medical therapies such as phosphodiesterase type 5 (PDE5) inhibitors and intracavernosal injection therapy of vasoactive agents, as well as vacuum erection devices and penile prosthesis implants in medically refractory cases. However, the [...] Read more.
Contemporary treatment algorithms for erectile dysfunction (ED) involve the use of medical therapies such as phosphodiesterase type 5 (PDE5) inhibitors and intracavernosal injection therapy of vasoactive agents, as well as vacuum erection devices and penile prosthesis implants in medically refractory cases. However, the current therapeutic options only address the symptoms of ED and not the underlying pathogenesis that results in ED. Newer and novel ED therapies aspire to reverse ED conditions by preventing cavernosal fibrosis, promoting endothelial revascularization and modulating various neuro-hormonal pathways. Regenerative therapeutic strategies such as low-intensity shock wave, gene and cellular-based therapies, and penile transplants are designed to improve penile hemodynamics and revitalize the cavernosal smooth muscle to mitigate and/or reverse underlying ED. This state-of-art article evaluates current and emerging therapeutic options for ED. Full article
(This article belongs to the Special Issue Men's Sexual Health)
12 pages, 388 KiB  
Review
Erectile Dysfunction: A Primer for in Office Management
Med. Sci. 2019, 7(9), 90; https://doi.org/10.3390/medsci7090090 - 29 Aug 2019
Cited by 1 | Viewed by 4695
Abstract
Introduction: Optimizing erectile dysfunction (ED) remains a clinically significant endeavor as insufficient outcomes from oral, injectable and even surgical approaches to treatment remain less than ideal. In this report, we integrate evolving knowledge and provide an algorithmic approach for the clinician to fine-tune [...] Read more.
Introduction: Optimizing erectile dysfunction (ED) remains a clinically significant endeavor as insufficient outcomes from oral, injectable and even surgical approaches to treatment remain less than ideal. In this report, we integrate evolving knowledge and provide an algorithmic approach for the clinician to fine-tune management. Methods: We performed a PubMed and Medline search of Erectile Dysfunction treatment optimization, enhanced patient efficacy for ED, and why men fail ED treatment. All relevant papers for the past two decades were reviewed. Results: Establishing the goals and objectives of the patient and partner while providing detailed instructions for treatment can minimize failures and create an environment that allows treatment optimization. A thorough work-up may identify reversible or contributing causes. We identified several areas where treatment of ED could be optimized. These include; management of associated medical conditions, lifestyle improvements, PDE5 inhibitor prescription strategies, management of hypogonadism and the initiation of intracavernosal injection therapy (ICI). Conclusions: In our view, once a man presents for help to the clinician, use of the simple strategies identified in this review to optimize the tolerability, safety and effectiveness of the selected treatment should result in enhanced patient and partner satisfaction, with improved outcomes. Full article
(This article belongs to the Special Issue Men's Sexual Health)
Show Figures

Figure 1

6 pages, 200 KiB  
Review
Contemporary and Novel Imaging Studies for the Evaluation of Erectile Dysfunction
Med. Sci. 2019, 7(8), 87; https://doi.org/10.3390/medsci7080087 - 09 Aug 2019
Cited by 3 | Viewed by 3126
Abstract
Traditionally, it was thought that the pathogenesis of erectile dysfunction (ED) can be divided into psychological and organic factors. However, recent literature supports the development and progression of ED due to multidimensional alterations of a complex interplay of central and peripheral systems, from [...] Read more.
Traditionally, it was thought that the pathogenesis of erectile dysfunction (ED) can be divided into psychological and organic factors. However, recent literature supports the development and progression of ED due to multidimensional alterations of a complex interplay of central and peripheral systems, from neural cognitive and efferent networks to loco-regional neuro-hormonal factors which are responsible for impaired penile vascular hemodynamics and ensuing lack of, or suboptimal, blood flow into the penis and/or veno-occlusive dysfunction. It is recognised that ED is strongly correlated with cardiovascular health and published clinical guidelines advocate screening for cardiovascular and metabolic risk factors in men presenting with ED. Over the past few decades, various imaging modalities have been developed and utilised to provide objective evaluation for ED to better characterise the state of penile health and exclude psychogenic components. The following article evaluates current and emerging imaging diagnostic tools for ED. Full article
(This article belongs to the Special Issue Men's Sexual Health)
13 pages, 248 KiB  
Review
The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological Limitations
Med. Sci. 2019, 7(8), 85; https://doi.org/10.3390/medsci7080085 - 05 Aug 2019
Cited by 14 | Viewed by 4027
Abstract
Multi-parametric magnetic resonance imaging (mpMRI) and positron emission tomography (PET) using prostate-specific membrane antigen (PSMA) targeting ligands have been adopted as a new standard of imaging modality in the management of prostate cancer (PCa). Technological advances with hybrid and advanced computer-assisted technologies such [...] Read more.
Multi-parametric magnetic resonance imaging (mpMRI) and positron emission tomography (PET) using prostate-specific membrane antigen (PSMA) targeting ligands have been adopted as a new standard of imaging modality in the management of prostate cancer (PCa). Technological advances with hybrid and advanced computer-assisted technologies such as MR/PET, MR/US, multi-parametric US, and robotic biopsy systems, have resulted in improved diagnosis and staging of patients in various stages of PCa with changes in treatment that may be considered “personalized”. Whilst newer clinical trials incorporate these novel imaging modalities into study protocols and as long-term data matures, patients should be made aware of the potential benefits and harm related to these technologies. Published literature needs to report longer-term treatment efficacy, health economic outcomes, and adverse effects. False positives and negatives of these imaging modalities have the potential to cause harm and the limitations of these technologies should be appreciated. The role of a multi-disciplinary team (MDT) and a shared-decision-making model are important to ensure that all aspects of the novel imaging modalities are considered. Full article
(This article belongs to the Special Issue Men's Sexual Health)
Back to TopTop